<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193333</url>
  </required_header>
  <id_info>
    <org_study_id>SOPH122-0316/III</org_study_id>
    <nct_id>NCT03193333</nct_id>
  </id_info>
  <brief_title>PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)</brief_title>
  <acronym>PRO-122LATAM</acronym>
  <official_title>A Non-inferiority in the Intraocular Pressure Decrease of the Preservative-free Ophthalmic Solution PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To evaluate the non-inferiority in the intraocular pressure decrease of the
      preservative-free ophthalmic solution PRO-122, manufactured by Laboratorios Sophia S.A. de
      C.V., versus concomitant therapy in subjects with uncontrolled primary open-angle glaucoma
      and/or IOP.

      Hypothesis: The mean (average) value of the IOP final absolute reduction in the experimental
      group (PRO-122) is not lower, considering a lower limit of 1 mmHg, compared to the IOP mean
      absolute reduction of the standard group (concomitant therapy).

      Methodology: A non-inferiority, phase III, double-blind, randomized, controlled, parallel,
      clinical trial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Number of patients: 51 subjects divided into 3 groups (17 subjects per group)

      Diagnosis and main inclusion criterion:

      Diagnosis: Primary open-angle glaucoma or ocular hypertension

      Main criteria:

        -  Patients of either sex

        -  Average intraocular pressure (IOP) ≤ 36 mm/Hg

        -  Previous management with ocular hypotensive medications ≥ 2 months, without achieving
           control (target IOP)

        -  Age ≥ 18 years

        -  Informed consent

      Test product, dosage and route of administration:

        -  PRO-122. Preservative-free ophthalmic solution of timolol 0.5% / brimonidine 0.2% /
           dorzolamide 2% Manufactured by Laboratorios Sophia, S.A. de C.V., Zapopan, Jalisco,
           Mexico. + Placebo + Placebo

        -  Dosage: 1 drop every 12 hours

        -  Route of administration: ophthalmic

      Treatment duration: 90 days

      Evaluation criteria:

      Efficiency (non-inferiority):

        -  IOP decrease

      Safety:

        -  Best corrected visual acuity

        -  Cup-to-disc ratio

        -  Visual fields determined by computerized perimetry

        -  Central corneal thickness determined by pachymetry

        -  Ocular surface integrity, including:

             -  Conjunctival hyperemia

             -  Chemosis

             -  Fluorescein staining

        -  Density of goblet cells

        -  Adverse events

      Tolerability:

        -  Ocular comfort index

      Statistical methodology:

      The data will be expressed with measures of central tendency: mean and standard deviation for
      quantitative variables. The qualitative variables will be presented in frequencies and
      percentages. Statistical analysis will be done by means of a Kruskal-Wallis test for
      quantitative variables. The difference between qualitative variables will be analyzed using
      an square chi An alpha ≤ 0.05 would be considered as significant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2017</start_date>
  <completion_date type="Anticipated">December 16, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A non-inferiority, phase III, double-blind, randomized, controlled, parallel, clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Blinding will be performed by the personnel assigned by the Laboratorios Sophia S.A. de C.V. Clinical Operations Management. The blinding will consist in the elimination of the primary label (commercial) for Krytantek Ofteno® and the triple concomitant therapy and the placement of a label identical to those of the other interventions. Since the bottles in which Krytantek Ofteno® and the concomitant therapies are different in color and cap shape to the ones used for the placebo and the PRO-122, a masking will be performed in the primary packaging, which shall be identical for all three interventions.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>intraocular pressure (IOP)</measure>
    <time_frame>90days</time_frame>
    <description>Intraocular pressure, Unit: Millimeters of mercury (mmHg) type of variable: Continuous, Measurement method: Goldman applanation tonometry. Normal intraocular pressure 11-21 mmHg</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Primary Open-angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>PRO-122 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To validate the 3 flasks of the triple therapy will be used 1 bottle with the three active principles (PRO-122) and two placebos and thus comply with the masking.
Drug substances: Timolol 5 mg/mL, brimonidine 2 mg/mL and dorzolamide 20 mg/mL. preservative free.
Pharmaceutical form: Ophthalmic solution
Made by: Laboratorios Sophia, S.A. de C.V.
Posology: 1 drop every 12 hours for 90 days
Description of the solution: clear, visibly particle free, slightly yellow solution, preservative free
Package description: 5 m multidose dropper bottle.
Placebo (for
Two pieces of approved placebo. Administered in 2 multidose dropper bottles.
Posology: 1 drop of each dropper bottle every 12 hours for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concomitant triple therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Imot Ofteno
Drug substance: Timolol 5 mg/mL
Pharmaceutical form: Ophthalmic solution
Made by Laboratorios Sophia S.A. de C.V.
Alphagan
Drug substance Brimonidine 2 mg/mL
Pharmaceutical form: Ophthalmic solution
Made by: Allergan, Inc.
Trusopt
Drug substance: Dorzolamide 20 mg/mL
Pharmaceutical form: Ophthalmic solution
Made by: Merck Sharp and Dohme Corp.
Posology: 1 drop every 12 hours for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Krytantek Ofteno Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To validate the three flasks of the triple therapy will be used 1 bottle with the three active principles (Krytantek) and two placebos and thus comply with the masking.
Drug substances: Timolol 5 mg/mL, brimonidine 2 mg/mL and dorzolamide 20 mg/mL.
Pharmaceutical form: Ophthalmic solution
Made by: Laboratorios Sophia, S.A. de C.V.
Posology: 1 drop every 12 hours for 90 days
Description of the solution: clear, visibly particle free, slightly yellow solution Package description: 5 m multidose dropper bottle.
Placebo (for two pieces of approved placebo. Administered in 2 multidose dropper bottles.
Posology: 1 drop of each dropper bottle every 12 hours for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO-122</intervention_name>
    <description>Posology: 1 drop every 12 hours for 90 days</description>
    <arm_group_label>PRO-122 group</arm_group_label>
    <other_name>krytantek PF (Timolol, Brimonidine, Dorzolamide)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol eye drops</intervention_name>
    <description>1 drop every 12 hours for 90 days</description>
    <arm_group_label>Concomitant triple therapy group</arm_group_label>
    <other_name>Concomitant triple therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dorzolamide-Timolol Ophthalmic</intervention_name>
    <description>1 drop every 12 hours for 90 days</description>
    <arm_group_label>Concomitant triple therapy group</arm_group_label>
    <other_name>Concomitant triple therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brimonidine Ophthalmic Solution</intervention_name>
    <description>1 drop every 12 hours for 90 days</description>
    <arm_group_label>Concomitant triple therapy group</arm_group_label>
    <other_name>Concomitant triple therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo1</intervention_name>
    <description>1 drop of each dropper bottle every 12 hours for 90 days</description>
    <arm_group_label>PRO-122 group</arm_group_label>
    <arm_group_label>Krytantek Ofteno Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo 2</intervention_name>
    <description>1 drop of each dropper bottle every 12 hours for 90 days</description>
    <arm_group_label>PRO-122 group</arm_group_label>
    <arm_group_label>Krytantek Ofteno Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Krytantek</intervention_name>
    <description>Posology: 1 drop every 12 hours for 90 days</description>
    <arm_group_label>Krytantek Ofteno Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Age greater or equal to 18 years

          -  Both sexes

          -  Women of childbearing age with birth control method

          -  Diagnosis of Primary open-angle glaucoma (according to the Guidelines of the Preferred
             Practice Pattern of the American Academy of Ophthalmology) or ocular hypertension
             (OHT)

          -  Intraocular pressure (IOP) not controlled with dual therapy according to the principal
             investigator (PI) judgment.

          -  IOP on the selection visit at 9 am, after the washing period, from 21 - 36 mmHg in at
             least one eye.

        Exclusion Criteria:

        General criteria

          -  Pregnant, breastfeeding or planning to get pregnant women.

          -  Women of childbearing age and who do not intake a hormonal contraceptive method,
             intrauterine device or bilateral tubal obstruction.

          -  Participation in another clinical research study greater or equal 30 days before the
             screening visit.

          -  People who cannot comply with their attendance at appointments or with all the -
             Protocol requirements

        Medical and therapeutic criteria:

          -  Anterior chamber angle grade less than 2 of Shaffer rating.

          -  Excavation of optic nerve greater than 0.80 horizontal or vertical (ratio cup-disc)

          -  Serious loss of central visual field in any eye (sensitivity less or equal to 10
             decibels in greater or equal to 2 of 4 points of the visual field test close to the
             fixation point)

          -  People not able to safely suspend ocular hypotensives drug products for the washout
             period according to the PI judgement.

          -  Chronic, recurrent, or active ocular inflammatory diseases (e.g. uveitis, scleritis,
             keratitis, herpetic) in any eye.

          -  Eye trauma less or equal to 6 months prior to the study

          -  Eye infection / inflammation less or equal to 3 months prior to the study

          -  Clinically significant or progressive retinal disease (e.g. degenerations, diabetic
             retinopathy, retinal detachment)

          -  Ability Visual 20/200 or worse in any of the eyes.

          -  Subject with only one eye

          -  Eye diseases that contraindicate the use of Beta-blocker (BB) Alpha-adrenergic agonist
             (AA) or Carbonic anhydrase inhibitors (CAIs)

          -  Intraocular surgery less or equal to 6 months prior to the study

          -  Laser intraocular surgery less or equal to 3 months prior to the study

          -  Any abnormality preventing reliable applanation tonometry

          -  Unstable or uncontrolled cardiovascular disease

          -  Chronic pulmonary disease (e.g. bronchial asthma)

          -  Any condition or illness that do not fit the subject for the study according to the PI
             judgment.

          -  Use of high doses of salicylate (1 g daily) less or equal to4 weeks before the
             eligibility visit

          -  In treatment with psychotropic medications that increase the adrenergic response

          -  Known hypersensitivity to BB medications (e.g. timolol), AA (e.g. brimonidine) and CAI
             (e.g. dorzolamide), sulfonamide derivatives, or any of the components of the study
             drugs

          -  Concomitant use of monoamine oxidase inhibitors

          -  Systemic or topical use of corticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leopoldo Baiza, MD</last_name>
    <role>Study Director</role>
    <affiliation>Laboratorios Sophia S.A de C.V.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ricardo Llamas, PhD</last_name>
    <phone>(33)30014200</phone>
    <phone_ext>1259</phone_ext>
    <email>ricardo.llamas@sophia.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Oscar Olvera, MD</last_name>
    <phone>(33)30014200</phone>
    <phone_ext>1074</phone_ext>
    <email>oscar.olvera@sophia.com.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MD. Sandra Belalcazar Rey</name>
      <address>
        <city>Bogotá</city>
        <state>Bogotá D.C.</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Cabrera, MD</last_name>
      <phone>+5713487333</phone>
      <phone_ext>1605</phone_ext>
    </contact>
    <contact_backup>
      <last_name>Claudia Carbajal, BD</last_name>
      <phone>+5713487333</phone>
      <phone_ext>1605</phone_ext>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>MD. Victoria Eugenia Sanchez Castellanos</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>44960</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Sanchez Castellanos, MD</last_name>
      <phone>+5213339152222</phone>
      <email>victoriaoftalmo@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Miguel Montes Salcedo, MD</last_name>
      <phone>+5213339152222</phone>
      <email>doctorlasik@yahoo.com.mx</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>primary open-angle glaucoma</keyword>
  <keyword>Ophthalmic antihypertensives</keyword>
  <keyword>Krytantek Ofteno®.</keyword>
  <keyword>timolol</keyword>
  <keyword>brimonidine</keyword>
  <keyword>dorzolamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Dorzolamide</mesh_term>
    <mesh_term>Brimonidine Tartrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

